2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.Peer-Reviewed Original ResearchConceptsStable diseasePartial responseMacrophage populationsThree-drug regimenUnconfirmed partial responsePhase I trialLimited treatment optionsMonocyte/macrophage populationNon-classical monocytesMurine melanoma modelTreatment-related changesResultsThirteen patientsWorse survivalI trialInflammatory tumorPatient populationTreatment optionsImmune cellsDisease progressionMurine studiesPreclinical modelsResistant melanomaAntigen presentationMurine modelCyTOF analysis
2016
The impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
Hafez N, Wang R, Hurwitz M, Ma X, Petrylak D. The impact of androgen deprivation and pelvic radiation on the development of bladder cancer. Journal Of Clinical Oncology 2016, 34: 439-439. DOI: 10.1200/jco.2016.34.2_suppl.439.Peer-Reviewed Original ResearchAndrogen deprivation therapyUrothelial bladder cancerProstate cancer patientsSecondary bladder cancerBladder cancerCancer patientsRadiation therapyAndrogen deprivationProstate cancerRecurrent urothelial bladder cancerElderly prostate cancer patientsCox proportional modelingRetrospective cohort studyKaplan-Meier analysisSEER-Medicare databaseSimilar patient populationsProstate cancer treatmentPrimary prostate cancerDeprivation therapyMedian followPelvic radiationCohort studyMale predilectionProportional modelingPatient population